Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class B G protein–coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three major tissues in humans, enteroendocrine L cells in the distal intestine, α cells in the pancreas, and the central nervous system, which exerts important actions useful in the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake. Peptidic analogs of GLP-1 have been successfully developed with enhanced bioavailability and pharmacological activity. Physiologic and biochemical studies with truncated, chimeric, and mutated peptides and GLP-1R variants, together with ligand-bound crystal structures of the extracellular domain and the first three-dimensional structures of the 7-helical transmembrane domain of class B GPCRs, have provided the basis for a two-domain–binding mechanism of GLP-1 with its cognate receptor. Although efforts in discovering therapeutically viable nonpeptidic GLP-1R agonists have been hampered, small-molecule modulators offer complementary chemical tools to peptide analogs to investigate ligand-directed biased cellular signaling of GLP-1R. The integrated pharmacological and structural information of different GLP-1 analogs and homologous receptors give new insights into the molecular determinants of GLP-1R ligand selectivity and functional activity, thereby providing novel opportunities in the design and development of more efficacious agents to treat metabolic disorders.

• Publication year

  2016

• Venue

  Pharmacological Reviews

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/pr.115.011395PMID 27630114PMCID 5050443
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pancreatic Islet Hyperplasia

  2018cited by this paper
• A role for Glucagon‐Like Peptide‐1 in the regulation of &bgr;‐cell autophagy

  2018cited by this paper
• The passing of the baton

  2018influential reference
• Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R)*

  2016influential reference
• Extra-helical binding site of a glucagon receptor antagonist

  2016influential reference
• Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation.

  2016influential reference
• Increased incidence of rheumatoid arthritis in multiple sclerosis

  2016influential reference
• Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments

  2016cited by this paper
• Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor

  2016influential reference
• A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures

  2016influential reference
• The non‐peptide GLP‐1 receptor agonist WB4‐24 blocks inflammatory nociception by stimulating β‐endorphin release from spinal microglia

  2015cited by this paper
• Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure

  2015influential reference
• Generic GPCR residue numbers - aligning topology maps while minding the gaps.

  2015cited by this paper
• Conformational states of the full-length glucagon receptor

  2015influential reference
• High Risk of Diabetes and Neurobehavioral Deficits in Individuals With Surgically Treated Hyperinsulinism.

  2015cited by this paper
• The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling

  2015cited by this paper
• Ligand Binding Pocket Formed by Evolutionarily Conserved Residues in the Glucagon-like Peptide-1 (GLP-1) Receptor Core Domain*

  2015cited by this paper
• Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.

  2015cited by this paper
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

  2015cited by this paper
• Novel Allosteric Modulators of G Protein-coupled Receptors*

  2015cited by this paper
• A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

  2015cited by this paper
• Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

  2015cited by this paper
• The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease

  2015cited by this paper
• Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Gαq pathway.

  2015influential reference
• GLP-1 based therapeutics: simultaneously combating T2DM and obesity

  2015cited by this paper
• Epac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytes.

  2015cited by this paper
• Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic β-cells via protein kinase A

  2015influential reference
• Molecular mechanisms of congenital hyperinsulinism.

  2015cited by this paper
• Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes.

  2015cited by this paper
• Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists.

  2015influential reference
• GLP-1 Receptor Agonists

  2015cited by this paper
• Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs - a nested case-control study.

  2015cited by this paper
• HTRF: a technology tailored for biomarker determination—novel analytical detection system suitable for detection of specific autoimmune antibodies as biomarkers in nanogram level in different body fluids

  2015cited by this paper
• Transformation of oligomers of lipidated peptide induced by change in pH.

  2015cited by this paper
• Differential Impact of Amino Acid Substitutions on Critical Residues of the Human Glucagon-Like Peptide-1 Receptor Involved in Peptide Activity and Small-Molecule Allostery

  2015influential reference
• GLP-1 receptor agonists: a review of head-to-head clinical studies

  2015cited by this paper
• Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors.

  2014cited by this paper
• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.

  2014cited by this paper
• The putative signal peptide of glucagon-like peptide-1 receptor is not required for receptor synthesis but promotes receptor expression

  2014cited by this paper
• A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification.

  2014influential reference
• Distribution of glucagon-like peptide 1-immunopositive neurons in human caudal medulla

  2014cited by this paper
• The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus

  2014cited by this paper
• Vildagliptin Stimulates Endothelial Cell Network Formation and Ischemia-induced Revascularization via an Endothelial Nitric-oxide Synthase-dependent Mechanism*

  2014cited by this paper
• Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications

  2014cited by this paper
• Functional Consequences of Glucagon-like Peptide-1 Receptor Cross-talk and Trafficking*

  2014cited by this paper
• Insights into the structure of class B GPCRs.

  2014influential reference
• Geniposide attenuates mitochondrial dysfunction and memory deficits in APP/PS1 transgenic mice.

  2014cited by this paper
• Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.

  2014cited by this paper
• Once-yearly device takes on daily and weekly diabetes drugs

  2014cited by this paper
• GLP‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents

  2014cited by this paper
• The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell Surface expression

  2014cited by this paper
• Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

  2014influential reference
• Better Glycemic Control and Less Weight Gain with Once Weekly Dulaglutide vs. Once Daily Insulin Glargine, Both Combined with Pre-Meal Insulin Lispro, in Type 2 Diabetes Patients (AWARD-4)

  2014cited by this paper
• Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?

  2014cited by this paper
• The role of glucagon on type 2 diabetes at a glance

  2014cited by this paper
• Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM)

  2014influential reference
• Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.

  2014cited by this paper
• Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

  2014cited by this paper
• Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast

  2014cited by this paper
• Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

  2014cited by this paper
• Biased Agonism at G Protein‐Coupled Receptors: The Promise and the Challenges—A Medicinal Chemistry Perspective

  2014cited by this paper
• GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

  2014cited by this paper
• Activation of Spinal Glucagon-Like Peptide-1 Receptors Specifically Suppresses Pain Hypersensitivity

  2014cited by this paper
• Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.

  2014influential reference
• The Epidemic of Thyroid Cancer in the United States: The Role of Endocrinologists and Ultrasounds

  2014cited by this paper
• Cardiovascular actions of incretin-based therapies.

  2014cited by this paper
• Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).

  2014cited by this paper
• Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

  2014cited by this paper
• Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)

  2014cited by this paper
• Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.

  2014cited by this paper
• Demonstration of the Innate Electrophilicity of 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor

  2013cited by this paper
• Pharmacology, physiology, and mechanisms of incretin hormone action.

  2013cited by this paper
• On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice

  2013cited by this paper
• Structure of class B GPCR corticotropin-releasing factor receptor 1

  2013influential reference
• Molecular signatures of G-protein-coupled receptors

  2013cited by this paper
• Structure of the human glucagon class B G-protein-coupled receptor

  2013cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

  2013cited by this paper
• Abnormal Neurodevelopmental Outcomes are Common in Children with Transient Congenital Hyperinsulinism

  2013cited by this paper
• Thyroid safety in patients treated with liraglutide

  2013cited by this paper
• Targeting GLP-1R for Non-Invasive Assessment of Pancreatic β-Cell Mass

  2013cited by this paper
• Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

  2013cited by this paper
• Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.

  2013cited by this paper
• Development of a cysteine-deprived and C-terminally truncated GLP-1 receptor.

  2013influential reference
• Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.

  2013cited by this paper
• Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations

  2013influential reference
• Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic β-cells.

  2013influential reference
• GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.

  2013cited by this paper
• Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function.

  2013cited by this paper
• Differential Activation and Modulation of the Glucagon-Like Peptide-1 Receptor by Small Molecule Ligands

  2013influential reference
• Pancreatitis-Diabetes-Pancreatic Cancer: Summary of an NIDDK-NCI Workshop

  2013cited by this paper
• Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes

  2013cited by this paper
• Exenatide and the treatment of patients with Parkinson's disease.

  2013cited by this paper
• A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction.

  2013influential reference
• Surface plasmon resonance applied to G protein-coupled receptors

  2013cited by this paper
• Action and therapeutic potential of oxyntomodulin

  2013influential reference
• Do GLP-1–Based Therapies Increase Cancer Risk?

  2013cited by this paper
• Emerging paradigms in GPCR allostery: implications for drug discovery

  2013influential reference
• Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.

  2012influential reference
• GLP-1 Receptor Antagonist Exendin-(9-39) Elevates Fasting Blood Glucose Levels in Congenital Hyperinsulinism Owing to Inactivating Mutations in the ATP-Sensitive K+ Channel

  2012cited by this paper

• Effects of chronic ethanol consumption on brain GLP-1R gene expression in mice and humans.

  2026cites this paper
• A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms

  2026cites this paper
• GLP-1 RAs for Treating Metabolic Dysfunction-Associated Steatosis Liver Disease: From GLP-1 Discovery to FDA Approval: A Comprehensive Narrative Review

  2026cites this paper
• Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon‐Like Peptide 1 Receptor Agonists

  2026cites this paper
• Metabolic dysfunction and mitochondrial failure in Alzheimer's disease: integrating pathophysiology, clinical evidence and emerging interventions

  2026cites this paper
• GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects

  2025cites this paper
• [A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide].

  2025cites this paper
• Type 2 Diabetes Mellitus Exacerbates Pathological Processes of Parkinson's Disease: Insights from Signaling Pathways Mediated by Insulin Receptors

  2025cites this paper
• Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review

  2025cites this paper
• A comprehensive Review of the Multi-System Benefits of Anti-Diabetic Drug Classes in Aging Beyond Glycemic Control

  2025cites this paper
• GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies.

  2025cites this paper
• Effects of GLP-1 analogs combined with physical exercise on total body mass in Individuals with obesity: a systematic review

  2025cites this paper
• The Cardiovascular Benefits of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.

  2025cites this paper
• Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data

  2025cites this paper
• Increased Cholesterol Interactions in the Active Conformational State of the Glucagon-Like Peptide-1 Receptor.

  2025cites this paper
• Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence

  2025cites this paper
• Insights into the structural dynamics of the secretin family (class B1) G protein-coupled receptors

  2025cites this paper
• The dual GLP-1 and GIP receptor agonist tirzapetide provides an unintended interaction with the β-adrenoceptors and plays a role in glucose metabolism in hyperglycemic or senescent cardiac cells

  2025cites this paper
• Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis

  2025cites this paper
• Characterizing the role of extracellular domain in GLP-1R biased agonism.

  2025cites this paper
• Glucagon receptor family in GtoPdb v.2025.3

  2025cites this paper
• Vibrational energy landscapes and energy flow in GPCRs: comparison between class A and class B GPCRs using all atom and coarse-grained models.

  2025cites this paper
• Diabetes Management Strategies: Review of Current Treatment Approaches

  2025cites this paper
• Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach

  2025cites this paper
• Effect of nipa palm (Nypa fruticans Wurmb.) vinegar on the incretin hormones and intestinal glucose transporters in type 2 diabetes mellitus rat model

  2025cites this paper
• Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review.

  2025cites this paper
• Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review

  2025cites this paper
• GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases, a Systematic Review of the Literature

  2025cites this paper
• Modulation of GLP-1 signalling as an innovative strategy counteracting the onset of heart failure: potential for natural compound supplementation.

  2025cites this paper
• Prolonged signaling of backbone-modified glucagon‐like peptide‐1 analogues with diverse receptor trafficking

  2025cites this paper
• GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives

  2025influential citation
• Spatially diffuse cAMP signalling with oppositely biased GLP-1 receptor agonists in β-cells despite differences in receptor localisation

  2025cites this paper
• Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.

  2025cites this paper
• Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes

  2025cites this paper
• Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells

  2025cites this paper
• Compare the Decrease in Visceral Adipose Tissue in People with Obesity and Prediabetes vs. Obesity and Type 2 Diabetes Treated with Liraglutide

  2025cites this paper
• Incretin‐Based Therapies in Alzheimer's and Parkinson's Disease: Advancing Neuroprotection With Dual and Triple Agonists—A Review

  2025cites this paper
• The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review

  2025cites this paper
• GzESTY as an optimized cell-based assay for initial steps in GPCR deorphanization

  2025cites this paper
• Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

  2025cites this paper
• Hyperglycemia in the focus of prevention of age-related skin changes

  2025cites this paper
• Computational assessment of the dimeric incretin GLP-1cpGLP-1 reveals the structural bases for its activity.

  2025cites this paper
• Exploration of natural compounds as potential negative allosteric modulators of glucagon-like peptide-1 receptor through molecular docking and dynamics simulation coupled with MM-GBSA binding energy calculations

  2025cites this paper
• Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies

  2025cites this paper
• Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases

  2025cites this paper
• Honey and lime juice flavonoids as potential adjunctive remedies against obesity and diabetes mellitus risks via glucagon receptor and glucagon-like peptide-1 receptor binding mechanisms: an in-silico investigation

  2025cites this paper
• Oral Treatment of Obesity by GLP-1 and Its Analogs

  2025cites this paper
• In-vitro, In-vivo, and In-silico Studies of Insulinotropic Activity and Cytotoxicity of Mahagony Seed Extracts and Its Nanophytosome

  2025cites this paper
• The expanding role of semaglutide: beyond glycemic control

  2025cites this paper
• Unraveling the sweet connection between pancreatic cancer and hyperglycemia.

  2025cites this paper
• Role of GLP-1 receptor agonists in sepsis and their therapeutic potential in sepsis-induced muscle atrophy (Review)

  2025cites this paper
• GLP-1R in diabetes mellitus: from basic discovery to therapeutics development

  2025cites this paper
• How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?

  2025cites this paper
• Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence

  2025cites this paper
• Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats

  2025cites this paper
• The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis

  2025cites this paper
• Anti-diabetic Biologicals: Exploring the Role of Different Analytical Techniques.

  2025cites this paper
• Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes

  2025cites this paper
• The impact of GLP-1 signalling on the energy metabolism of pancreatic islet β-cells and extrapancreatic tissues.

  2024cites this paper
• Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells

  2024influential citation
• Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population

  2024cites this paper
• Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects

  2024cites this paper
• Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity

  2024cites this paper
• Orthopalladated imidazolones and thiazolones: synthesis, photophysical properties and photochemical reactivity.

  2024cites this paper
• Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry.

  2024cites this paper
• G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery

  2024cites this paper
• Lipid regulation of the glucagon receptor family

  2024cites this paper
• From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist’s Dual Role in Prostate Cancer

  2024cites this paper
• A new trivalent recombinant protein for type 2 diabetes mellitus with oral delivery potential: design, expression, and experimental validation

  2024cites this paper
• Intestinal Perfusion of Unacylated Ghrelin Alleviated Metabolic Associated Fatty Liver Disease in Rat via a Central Glucagon-Like Peptide-1 Pathway.

  2024cites this paper
• Prolonged signaling of backbone-modified glucagon-like peptide-1 analogues with diverse receptor trafficking

  2024cites this paper
• GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review.

  2024cites this paper
• Chickpea proteins are potential sources of bioactive peptides that induce glucose uptake via AMP-activated protein kinase

  2024cites this paper
• Effect of Glucagon-like Peptide-1 Receptor Agonism on Aortic Valve Stenosis Risk: A Mendelian Randomization Analysis

  2024cites this paper
• Comparative analysis of newer classes of antidiabetics and the concept of pharmaceutical care – dealing with therapeutic problems

  2024cites this paper
• Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review

  2024cites this paper
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

  2024cites this paper
• Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor’s anti-inflammatory effects

  2024cites this paper
• Association Between Dipeptidyl Peptidase-4 Inhibitor Use and Cognitive Functions, Brain-Derived Neurotrophic Factor, and Pentraxin-3 Levels in Patients With Type 2 Diabetes

  2024cites this paper
• GLP-1RAs attenuated obesity and reversed leptin resistance partly via activating the microbiome-derived inosine/A2A pathway

  2024cites this paper
• Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities

  2024cites this paper
• Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.

  2024cites this paper
• Endogenous cell membrane interactome mapping for the GLP-1 receptor in different cell types

  2024cites this paper
• Emerging role of antidiabetic drugs in cardiorenal protection

  2024cites this paper
• Insights into the structure and activation mechanism of some class B1 GPCR family members

  2024cites this paper
• Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care

  2024cites this paper
• The G Protein-First Mechanism for Activation of the Class B Glucagon-like Peptide 1 Receptor Coupled to N-Terminal Domain-Mediated Conformational Progression.

  2024cites this paper
• Curcumin alone not combined with piperine exerts cardioprotective effects in pressure-overload rats by increasing glucagon-like peptide-1 receptor signaling and additional properties

  2024cites this paper
• The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype

  2024cites this paper
• Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

  2024cites this paper
• Receptors and Signaling Pathways Controlling Beta-Cell Function and Survival as Targets for Anti-Diabetic Therapeutic Strategies

  2024cites this paper
• Baicalein Ameliorates Insulin Resistance of HFD/STZ Mice Through Activating PI3K/AKT Signal Pathway of Liver and Skeletal Muscle in a GLP-1R-Dependent Manner

  2024cites this paper
• Gz Enhanced Signal Transduction assaY (GZESTY) for GPCR deorphanization

  2024cites this paper
• The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update

  2024cites this paper
• G protein-coupled receptor-biased signaling: potential drug discovery to facilitate treatment of metabolic diseases

  2024cites this paper
• Synthesis and biological studies of 2-aminothiophene derivatives as positive allosteric modulators of glucagon-like peptide 1 receptor.

  2024cites this paper
• The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function

  2024cites this paper
• Disulfide-Directed Multicyclic Peptides with N-Terminally Extendable α-Helices for Recognition and Activation of G-Protein-Coupled Receptors.

  2024cites this paper
• Prolonged Activation of the GLP-1 Receptor via Covalent Capture.

  2024cites this paper
• The synergistic potential of GLP-1R agonist dulaglutide and ghrelin receptor analogue anamorelin in ameliorating muscle atrophy

  2024cites this paper